98%
921
2 minutes
20
A 29-year-old man with advanced hilar cholangiocarcinoma was successfully treated with an extended right lobectomy. The carbohydrate antigen 19-9 (CA19-9) level was elevated to 939 IU/l, and the pathological findings revealed moderately differentiated tubular adenocarcinoma which involved almost the entire thickness of the hepatic duct and the adjacent liver tissue (T3) and which was associated with lymph node metastasis (N1). It was a stage IIB (T3N1M0) tubular adenocarcinoma according to UICC pathological staging. Immunohistochemical examination revealed that Ki-67, cyclin D1, and MMP-7 were positive, and 14-3-3sigma and p27 were negative. The pathological and immunohistochemical findings indicated high malignant potential indicating poor prognosis. We administrated the postoperative adjunct gemcitabine combined with S-1 chemotherapy. The patient is alive without recurrence and doing well two years after surgery. We also review other reports of cholangiocarcinoma patients aged less than 30 years.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929407 | PMC |
http://dx.doi.org/10.1159/000313791 | DOI Listing |
Int J Surg Case Rep
September 2025
Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Yunnan Province, China. Electronic address:
Introduction: Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin lymphoma (NHL), originates primarily from lymph nodes, with a small proportion arising extranodally in sites such as the gastrointestinal tract and central nervous system. Given the general absence of lymphoid tissue in the bladder, primary bladder DLBCL is exceptionally rare.
Case Presentation: This case report describes an 83-year-old male patient with a bladder mass, initially suspected as cystitis glandularis, ultimately diagnosed via pathological examination as DLBCL.
Int J Surg Pathol
September 2025
Department of Pathology, The Thirteenth People's Hospital of Chongqing, Chongqing, China.
Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal cells. Recent advancements in genomic profiling have identified novel gene fusions in these tumors, offering new insights into their pathogenesis and potential therapeutic targets. Here, we describe a spindle cell sarcoma harboring a novel gene fusion.
View Article and Find Full Text PDFSaudi Dent J
September 2025
Oral Biology Department, Faculty of Dentistry, Ain Shams University, Cairo, Egypt.
To compare the efficacy of using bone marrow mesenchymal stem cell (BM-MSC) exosomes and injectable platelet rich fibrin (i-PRF) on the submandibular salivary glands (SMGs) of aged albino rats in restoring salivary gland structure and function. A total of 40 healthy male albino rats were used, two for obtaining the BM-MSCs, 10 for i-PRF preparation and seven adult rats (6-8 months old) represented the control group (Group 1). The remaining 21 rats were aged (18-20 months old) and divided into three groups of seven rats each; (Group 2): received no treatment, (Group 3): each rat received a single intraglandular injection of BM-MSC exosomes (50 μg/kg/dose suspended in 0.
View Article and Find Full Text PDFSurg Case Rep
September 2025
Department of Pathology, Self-Defense Forces Central Hospital, Tokyo, Japan.
Introduction: Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that most commonly originates in the pleura but can also occur at extrapleural sites, including the abdominal cavity. Among these, primary SFT of the stomach is exceptionally rare. Due to overlapping clinical, endoscopic, and radiologic characteristics, distinguishing SFT from gastrointestinal stromal tumor (GIST) can be particularly challenging.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Background: Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is resistant to chemotherapy and is associated with poor prognosis. Pediatric gastric cancer has an incidence of 0.02% among gastric cancer patients, with a median survival of 5 months.
View Article and Find Full Text PDF